The Use of Nutropin Depot in HIV-infected Adult Males
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00286676|
Recruitment Status : Withdrawn
First Posted : February 3, 2006
Last Update Posted : December 26, 2018
This is a pilot study. We will treat 10 HIV-infected adults (1/2 with lipoatrophy) with GH depot for one year. Results will be compared to data from 10 HIV patients (1/2 with lipoatrophy), treated with Nutropin AQ subcutaneously. The primary endpoint of the study is to determine the effect of GH depot on body weight and lean tissue mass (LTM).
The secondary endpoints are to document changes in: 1) whole body protein turnover (WBPT), 2) gluconeogenesis, 3) bone mineral density and markers of bone turnover, 4) fat distribution (lipoatrophy), 5) thymus size, 6) T-cell subsets, and 7) TNF-µ levels. Adverse events, such as glucose intolerance and edema, will be monitored at every visit.
|Condition or disease||Intervention/treatment||Phase|
|HIV Infection||Drug: Nutropin Procedure: Oral Glucose Tolerance Test Procedure: Dual Energy X-ray Absorptiometry (DEXA) Procedure: Computed Tomography (CT) Scan||Phase 2 Phase 3|
Patients will be recruited from the HIV clinics at University of Texas Southwestern Medical School and the Veterans Administration Hospital by direct invitation from Dr. Margolis (adult HIV clinic director and University director for the NIH-ACTG). We will recruit 20 HIV-infected adult males who have been treated with stable protease inhibitor therapy regimen for the past 6 months. One half of the subjects will have evidence of lipoatrophy (as defined by the ACTG29). Each subject will have baseline (BL) measures made, and then will start on GH depot or subcutaneous AQ. Patients will be followed every two weeks for the first six weeks, then every three months for the remainder of the study. Study parameters to be measured include (also see flow chart in appendix):
- Baseline, 3, 6 and 12 months: OGTT, testosterone level, whole body protein turnover, hepatic glucose production and gluconeogenesis measures, DXA scan (for measuring lean tissue mass and bone density), bone mineral markers, resting energy expenditure, calorie count, T cell subsets, TNF µ levels.
- Every 3 months: IGF-1 (will obtain every 2 weeks for first 6 weeks), body weight, and post-prandial glucose level.
- Baseline, 6 and 12 months- CT scan for measurement of thymus size
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Estimated Study Start Date :||February 1, 2006|
|Estimated Primary Completion Date :||February 1, 2006|
|Estimated Study Completion Date :||February 1, 2006|
- 1) body weight
- 2) lean tissue mass (LTM).
- Testosterone levels
- 1) whole body protein turnover (WBPT)
- 2) gluconeogenesis
- 3) bone mineral density and markers of bone turnover
- 4) fat distribution (lipoatrophy)
- 5) thymus size
- 6) T-cell subsets
- 7) TNF-µ level
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00286676
|United States, Texas|
|Aston Ambulatory Care Center|
|Dallas, Texas, United States, 75390|
|Parkland Health & Hospital System|
|Dallas, Texas, United States, 75390|
|Veteran's Affairs Medical Center|
|Dallas, Texas, United States|
|Principal Investigator:||Dana S Hardin, MD||University of Texas, Southwestern Medical Center at Dallas|